CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Pembrolizumab (Keytruda) for Mismatch Repair Deficient Endometrial Cancer - Details

Brand Name Keytruda
Generic Name Pembrolizumab
Tumour Type Gynecology
Indication Adult patients with unresectable or metastatic microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR) endometrial cancer whose tumours have progressed following prior therapy and who have no satisfactory alternative treatment options, as monotherapy.
Review Status Not Filed
Clarification CADTH is unable to recommend reimbursement because a submission was not filed by the manufacturer.
Pre Noc Submission
NOC Date
Manufacturer Merck Canada Inc.
Submission Date (Target Date)
Submission Type Non-Submission
Prioritization Requested
Stakeholder Input Deadline (target date based on target submission date) ‡
Check-point meeting (target date)
pERC Meeting (target date)
Initial Recommendation Issued (target date)
Feedback Deadline (target date) ‡
pERC Reconsideration Meeting (target date)
Final Recommendation Issued (target date)
Notification to Implement Issued

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.